Nanobodies®: new ammunition to battle viruses.
- Autores
- Vanlandschoot, Peter; Stortelers, Catelijne; Beirnaert, Els; Ibañez, Lorena Itatí; Schepens, Bert; Depla, Erik; Saelens, Xavier
- Año de publicación
- 2011
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- In 1989, a new type of antibody was identified, first in the sera of dromedaries and later also in all other species of the Camelidae family. These antibodies do not contain a light chain and also lack the first constant heavy domain. Today it is still unclear what the evolutionary advantage of such heavy chain-only antibodies could be. In sharp contrast, the broad applicability of the isolated variable antigen-binding domains (VHH) was rapidly recognized, especially for the development of therapeutic proteins, called Nanobodies¯. Here we summarize first some of the unique characteristics and features of VHHs. These will next be described in the context of different experimental therapeutic applications of Nanobodies against different viruses: HIV, Hepatitis B virus, influenza virus, Respiratory Syncytial virus, Rabies virus, FMDV, Poliovirus, Rotavirus, and PERVs. Next, the diagnostic application of VHHs (Vaccinia virus, Marburg virus and plant Tulip virus X), as well as an industrial application (lytic lactococcal 936 phage) will be described. In addition, the described data show that monovalent Nanobodies can possess unique characteristics not observed with conventional antibodies. The straightforward formatting into bivalent, multivalent, and/or multispecific Nanobodies allowed tailoring molecules for potency and cross-reactivity against viral targets with high sequence diversity.
Fil: Vanlandschoot, Peter. No especifíca;
Fil: Stortelers, Catelijne. No especifíca;
Fil: Beirnaert, Els. No especifíca;
Fil: Ibañez, Lorena Itatí. University of Ghent; Bélgica. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Schepens, Bert. University of Ghent; Bélgica
Fil: Depla, Erik. No especifíca;
Fil: Saelens, Xavier. University of Ghent; Bélgica - Materia
-
ANTIVIRAL
CAMELIDAE
HEAVY CHAIN-ONLY ANTIBODY
NANOBODY
VHH - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/194326
Ver los metadatos del registro completo
id |
CONICETDig_dcfde1f9531589e5b5d2015a23c91df8 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/194326 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Nanobodies®: new ammunition to battle viruses.Vanlandschoot, PeterStortelers, CatelijneBeirnaert, ElsIbañez, Lorena ItatíSchepens, BertDepla, ErikSaelens, XavierANTIVIRALCAMELIDAEHEAVY CHAIN-ONLY ANTIBODYNANOBODYVHHhttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1https://purl.org/becyt/ford/2.10https://purl.org/becyt/ford/2In 1989, a new type of antibody was identified, first in the sera of dromedaries and later also in all other species of the Camelidae family. These antibodies do not contain a light chain and also lack the first constant heavy domain. Today it is still unclear what the evolutionary advantage of such heavy chain-only antibodies could be. In sharp contrast, the broad applicability of the isolated variable antigen-binding domains (VHH) was rapidly recognized, especially for the development of therapeutic proteins, called Nanobodies¯. Here we summarize first some of the unique characteristics and features of VHHs. These will next be described in the context of different experimental therapeutic applications of Nanobodies against different viruses: HIV, Hepatitis B virus, influenza virus, Respiratory Syncytial virus, Rabies virus, FMDV, Poliovirus, Rotavirus, and PERVs. Next, the diagnostic application of VHHs (Vaccinia virus, Marburg virus and plant Tulip virus X), as well as an industrial application (lytic lactococcal 936 phage) will be described. In addition, the described data show that monovalent Nanobodies can possess unique characteristics not observed with conventional antibodies. The straightforward formatting into bivalent, multivalent, and/or multispecific Nanobodies allowed tailoring molecules for potency and cross-reactivity against viral targets with high sequence diversity.Fil: Vanlandschoot, Peter. No especifíca;Fil: Stortelers, Catelijne. No especifíca;Fil: Beirnaert, Els. No especifíca;Fil: Ibañez, Lorena Itatí. University of Ghent; Bélgica. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Schepens, Bert. University of Ghent; BélgicaFil: Depla, Erik. No especifíca;Fil: Saelens, Xavier. University of Ghent; BélgicaElsevier Science2011-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/194326Vanlandschoot, Peter; Stortelers, Catelijne; Beirnaert, Els; Ibañez, Lorena Itatí; Schepens, Bert; et al.; Nanobodies®: new ammunition to battle viruses.; Elsevier Science; Antiviral Research; 92; 3; 12-2011; 389-4070166-3542CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1016/j.antiviral.2011.09.002info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0166354211004402info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:54:52Zoai:ri.conicet.gov.ar:11336/194326instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:54:53.095CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Nanobodies®: new ammunition to battle viruses. |
title |
Nanobodies®: new ammunition to battle viruses. |
spellingShingle |
Nanobodies®: new ammunition to battle viruses. Vanlandschoot, Peter ANTIVIRAL CAMELIDAE HEAVY CHAIN-ONLY ANTIBODY NANOBODY VHH |
title_short |
Nanobodies®: new ammunition to battle viruses. |
title_full |
Nanobodies®: new ammunition to battle viruses. |
title_fullStr |
Nanobodies®: new ammunition to battle viruses. |
title_full_unstemmed |
Nanobodies®: new ammunition to battle viruses. |
title_sort |
Nanobodies®: new ammunition to battle viruses. |
dc.creator.none.fl_str_mv |
Vanlandschoot, Peter Stortelers, Catelijne Beirnaert, Els Ibañez, Lorena Itatí Schepens, Bert Depla, Erik Saelens, Xavier |
author |
Vanlandschoot, Peter |
author_facet |
Vanlandschoot, Peter Stortelers, Catelijne Beirnaert, Els Ibañez, Lorena Itatí Schepens, Bert Depla, Erik Saelens, Xavier |
author_role |
author |
author2 |
Stortelers, Catelijne Beirnaert, Els Ibañez, Lorena Itatí Schepens, Bert Depla, Erik Saelens, Xavier |
author2_role |
author author author author author author |
dc.subject.none.fl_str_mv |
ANTIVIRAL CAMELIDAE HEAVY CHAIN-ONLY ANTIBODY NANOBODY VHH |
topic |
ANTIVIRAL CAMELIDAE HEAVY CHAIN-ONLY ANTIBODY NANOBODY VHH |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/1.6 https://purl.org/becyt/ford/1 https://purl.org/becyt/ford/2.10 https://purl.org/becyt/ford/2 |
dc.description.none.fl_txt_mv |
In 1989, a new type of antibody was identified, first in the sera of dromedaries and later also in all other species of the Camelidae family. These antibodies do not contain a light chain and also lack the first constant heavy domain. Today it is still unclear what the evolutionary advantage of such heavy chain-only antibodies could be. In sharp contrast, the broad applicability of the isolated variable antigen-binding domains (VHH) was rapidly recognized, especially for the development of therapeutic proteins, called Nanobodies¯. Here we summarize first some of the unique characteristics and features of VHHs. These will next be described in the context of different experimental therapeutic applications of Nanobodies against different viruses: HIV, Hepatitis B virus, influenza virus, Respiratory Syncytial virus, Rabies virus, FMDV, Poliovirus, Rotavirus, and PERVs. Next, the diagnostic application of VHHs (Vaccinia virus, Marburg virus and plant Tulip virus X), as well as an industrial application (lytic lactococcal 936 phage) will be described. In addition, the described data show that monovalent Nanobodies can possess unique characteristics not observed with conventional antibodies. The straightforward formatting into bivalent, multivalent, and/or multispecific Nanobodies allowed tailoring molecules for potency and cross-reactivity against viral targets with high sequence diversity. Fil: Vanlandschoot, Peter. No especifíca; Fil: Stortelers, Catelijne. No especifíca; Fil: Beirnaert, Els. No especifíca; Fil: Ibañez, Lorena Itatí. University of Ghent; Bélgica. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Schepens, Bert. University of Ghent; Bélgica Fil: Depla, Erik. No especifíca; Fil: Saelens, Xavier. University of Ghent; Bélgica |
description |
In 1989, a new type of antibody was identified, first in the sera of dromedaries and later also in all other species of the Camelidae family. These antibodies do not contain a light chain and also lack the first constant heavy domain. Today it is still unclear what the evolutionary advantage of such heavy chain-only antibodies could be. In sharp contrast, the broad applicability of the isolated variable antigen-binding domains (VHH) was rapidly recognized, especially for the development of therapeutic proteins, called Nanobodies¯. Here we summarize first some of the unique characteristics and features of VHHs. These will next be described in the context of different experimental therapeutic applications of Nanobodies against different viruses: HIV, Hepatitis B virus, influenza virus, Respiratory Syncytial virus, Rabies virus, FMDV, Poliovirus, Rotavirus, and PERVs. Next, the diagnostic application of VHHs (Vaccinia virus, Marburg virus and plant Tulip virus X), as well as an industrial application (lytic lactococcal 936 phage) will be described. In addition, the described data show that monovalent Nanobodies can possess unique characteristics not observed with conventional antibodies. The straightforward formatting into bivalent, multivalent, and/or multispecific Nanobodies allowed tailoring molecules for potency and cross-reactivity against viral targets with high sequence diversity. |
publishDate |
2011 |
dc.date.none.fl_str_mv |
2011-12 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/194326 Vanlandschoot, Peter; Stortelers, Catelijne; Beirnaert, Els; Ibañez, Lorena Itatí; Schepens, Bert; et al.; Nanobodies®: new ammunition to battle viruses.; Elsevier Science; Antiviral Research; 92; 3; 12-2011; 389-407 0166-3542 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/194326 |
identifier_str_mv |
Vanlandschoot, Peter; Stortelers, Catelijne; Beirnaert, Els; Ibañez, Lorena Itatí; Schepens, Bert; et al.; Nanobodies®: new ammunition to battle viruses.; Elsevier Science; Antiviral Research; 92; 3; 12-2011; 389-407 0166-3542 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.antiviral.2011.09.002 info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0166354211004402 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier Science |
publisher.none.fl_str_mv |
Elsevier Science |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842269311996002304 |
score |
13.13397 |